NEW YORK, June 30, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Merck & Co., Inc. (NYSE: MRK), Johnson & Johnson (NYSE: JNJ), AbbVie Inc (NYSE: ABBV), Valeant Pharmaceuticals Intl Inc (NYSE: VRX) and GlaxoSmithKline plc (ADR) (NYSE: GSK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4237-100free.
--
Merck & Co., Inc. Analyst Notes
On June 23, 2014, Merck & Co., Inc. (Merck) announced that it will hold its Q2 2014 sales and earnings conference call on Tuesday, July 29, 2014, at 8:00 a.m. EDT, to provide an overview of the Company's performance for the quarter. According to Merck, a live audio webcast and a replay of the same for 12 months can be accessed through its website. Additionally the quarter's sales and earnings news release and supplemental financial disclosures will also be available in the Newsroom and Investor sections of the Company's website. The full analyst notes on Merck are available to download free of charge at:
http://www.analystsreview.com/Jun-30-2014/MRK/report.pdf
--
Johnson & Johnson Analyst Notes
On June 18, 2014, Janssen Pharmaceuticals, Inc., a part of the Janssen Pharmaceuticals Companies of Johnson & Johnson, announced that it has entered into an exclusive license agreement with Vertex Pharmaceuticals for the worldwide development, manufacturing, and commercialization of VX-787. According to the Company, VX-787 is a novel medicine in Phase II development for the treatment of influenza A, and is developed to directly inhibit replication of the influenza A virus, including recent H1 (pandemic) and H5 (avian) influenza strains. Under the license agreement, the Company also has the rights to develop, manufacture, and commercialize VX-787's back-up compound, VX-353, as well as certain other back-up compounds for the prevention and/or treatment of influenza. According to the Company, the agreement is subject to the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. The full analyst notes on Johnson & Johnson are available to download free of charge at:
http://www.analystsreview.com/Jun-30-2014/JNJ/report.pdf
--
AbbVie Inc Analyst Notes
On June 19, 2014, the Board of Directors of AbbVie Inc has declared a quarterly cash dividend of $0.42 per share, payable on August 15, 2014, to stockholders of record at the close of business as on July 15, 2014. The full analyst notes on AbbVie are available to download free of charge at:
http://www.analystsreview.com/Jun-30-2014/ABBV/report.pdf
--
Valeant Pharmaceuticals Intl Inc Analyst Notes
On June 25, 2014, Valeant Pharmaceuticals Intl Inc (Valeant) announced that it has filed a preliminary proxy statement for a special meeting of shareholders to consider and vote upon a proposal to approve the issuance of Valeant common shares, in connection with an acquisition of Allergan, Inc. The Company informed that it has started an exchange offer for Allergan's common stock on June 18, 2014. J. Michael Pearson, Chairman and CEO of Valeant said, "Today is another step forward in our pursuit of a combination with Allergan. Filing our preliminary proxy statement and holding a special meeting will give our shareholders a chance to show their support for our bid for Allergan and the value to be created in a combination with Allergan." The full analyst notes on Valeant are available to download free of charge at:
http://www.analystsreview.com/Jun-30-2014/VRX/report.pdf
--
GlaxoSmithKline plc (ADR) Analyst Notes
On June 25, 2014, GlaxoSmithKline plc (GSK) announced the start of a Phase III study, SUPPORT (TRC112121), to evaluate the platelet supportive care effects of eltrombopag (Promacta™/Revolade™) combined with azacitidine- the current standard of care, versus placebo combined with azacitidine in intermediate-1, intermediate-2 or high-risk patients with myelodysplastic syndromes (MDS). According to the GSK, MDS is a type of cancer where the bone marrow does not make enough healthy blood cells, and there are abnormal (blast) cells in the blood and/or bone marrow. The Company stated that the global study will assess the proportion of platelet transfusion-free patients during the first four cycles of treatment. Dr. Rafael Amado, Senior Vice President Oncology R&D at GSK, said, "Cytopenias are important complications of MDS which tend to worsen with azacitidine treatment. Currently, there are no approved treatments for MDS that stimulate platelet production. The initiation of this study is an important step toward providing a potential treatment option that may support platelets and avoid transfusions in thromobocytopenic patients with MDS undergoing chemotherapy treatment." The full analyst notes on GSK are available to download free of charge at:
http://www.analystsreview.com/Jun-30-2014/GSK/report.pdf
--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
AnalystsReview.com
SOURCE Analysts Review
